Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the United States in a committment designed to influence upcoming Trump administrati ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...

Drugmaker Eli Lilly plans to invest up to $27 billion to build four new pharmaceutical manufacturing sites in the U.S., the ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...